[go: up one dir, main page]

WO2006003179A3 - Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use - Google Patents

Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use Download PDF

Info

Publication number
WO2006003179A3
WO2006003179A3 PCT/EP2005/053122 EP2005053122W WO2006003179A3 WO 2006003179 A3 WO2006003179 A3 WO 2006003179A3 EP 2005053122 W EP2005053122 W EP 2005053122W WO 2006003179 A3 WO2006003179 A3 WO 2006003179A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
kir2ds4
therapeutic use
antibodies binding
cytotoxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/053122
Other languages
French (fr)
Other versions
WO2006003179A2 (en
Inventor
Alessandro Moretta
Chiesa Mariella Della
Pascale Andre
Laurent Gauthier
Francois Romagne
Peter Andreas Nicolai Wagtmann
Ivan Svendsen
Stefan Zahn
Anders Svensson
Matthias Thorolfsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Innate Pharma SA
DIMES Dipartimento di Medicina Sperimentale Universita degli Studi di Genova
Original Assignee
Novo Nordisk AS
Innate Pharma SA
DIMES Dipartimento di Medicina Sperimentale Universita degli Studi di Genova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2004/002464 external-priority patent/WO2005003172A2/en
Priority to KR1020077000069A priority Critical patent/KR101299167B1/en
Priority to CN200580022633.1A priority patent/CN1997670B/en
Priority to EP05758642A priority patent/EP1791868B1/en
Priority to DE602005026538T priority patent/DE602005026538D1/en
Priority to PL10178924T priority patent/PL2287195T3/en
Priority to JP2007518617A priority patent/JP5112863B2/en
Priority to EP10178924.6A priority patent/EP2287195B1/en
Priority to ES05758642T priority patent/ES2360467T3/en
Priority to CA2601417A priority patent/CA2601417C/en
Priority to AT05758642T priority patent/ATE499386T1/en
Priority to DK05758642.2T priority patent/DK1791868T3/en
Priority to AU2005259221A priority patent/AU2005259221B2/en
Priority to MX2007000210A priority patent/MX2007000210A/en
Application filed by Novo Nordisk AS, Innate Pharma SA, DIMES Dipartimento di Medicina Sperimentale Universita degli Studi di Genova filed Critical Novo Nordisk AS
Priority to BRPI0512911-7A priority patent/BRPI0512911B1/en
Publication of WO2006003179A2 publication Critical patent/WO2006003179A2/en
Publication of WO2006003179A3 publication Critical patent/WO2006003179A3/en
Priority to IL179635A priority patent/IL179635A0/en
Anticipated expiration legal-status Critical
Priority to ZA2007/00736A priority patent/ZA200700736B/en
Priority to NO20070585A priority patent/NO341198B1/en
Priority to US12/244,170 priority patent/US8119775B2/en
Priority to US13/347,832 priority patent/US8614307B2/en
Priority to US13/936,486 priority patent/US8981065B2/en
Priority to US14/659,045 priority patent/US20150191547A1/en
Priority to US14/829,170 priority patent/US20150344576A1/en
Priority to NO20171133A priority patent/NO344566B1/en
Priority to CY20191100871T priority patent/CY1122391T1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Compositions and methods for regulating an immune response in a subject are de­scribed. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1­4F1. Described also are also fragments and derivatives of such antibodies, as well as phar­maceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.
PCT/EP2005/053122 2004-07-01 2005-07-01 Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use Ceased WO2006003179A2 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
AU2005259221A AU2005259221B2 (en) 2004-07-01 2005-07-01 Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
BRPI0512911-7A BRPI0512911B1 (en) 2004-07-01 2005-07-01 ISOLATED HUMAN ANTIBODY, NUCLEIC ACID, VECTOR, CELL, METHOD OF PRODUCING A HUMAN ANTI-KIR ANTIBODY, PHARMACEUTICAL COMPOSITION, AND METHOD OF ENHANCED NK CELL ACTIVITY IN A PATIENT IN NEED OF THE SAME
EP05758642A EP1791868B1 (en) 2004-07-01 2005-07-01 Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
DE602005026538T DE602005026538D1 (en) 2004-07-01 2005-07-01 TO THE RECEPTORS KIR2DL1, -2, -3, BUT NOT KIR2DS4, BINDING ANTIBODIES AND THEIR THERAPEUTIC USE
PL10178924T PL2287195T3 (en) 2004-07-01 2005-07-01 Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
JP2007518617A JP5112863B2 (en) 2004-07-01 2005-07-01 Human anti-KIR antibody
EP10178924.6A EP2287195B1 (en) 2004-07-01 2005-07-01 Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
ES05758642T ES2360467T3 (en) 2004-07-01 2005-07-01 ANTIBODIES THAT JOIN KIR2DL1, -2, -3 RECEPTORS BUT NOT KIR2DS4 AND THERAPEUTIC USE.
CA2601417A CA2601417C (en) 2004-07-01 2005-07-01 Human anti-kir antibodies
AT05758642T ATE499386T1 (en) 2004-07-01 2005-07-01 ANTIBODIES BINDING TO THE RECEPTORS KIR2DL1, -2, -3, BUT NOT KIR2DS4, AND THEIR THERAPEUTIC USE
DK05758642.2T DK1791868T3 (en) 2004-07-01 2005-07-01 Antibodies that bind to receptors KIR2DL1, -2, 3 but not KIR2DS4, as well as therapeutic use
CN200580022633.1A CN1997670B (en) 2004-07-01 2005-07-01 Human anti-KIR antibodies
MX2007000210A MX2007000210A (en) 2004-07-01 2005-07-01 Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use.
KR1020077000069A KR101299167B1 (en) 2004-07-01 2005-07-01 Human anti-kir antibodies
IL179635A IL179635A0 (en) 2004-07-01 2006-11-27 Human anti-kir antibodies
ZA2007/00736A ZA200700736B (en) 2004-07-01 2007-01-26 Human anti-kir antibodies
NO20070585A NO341198B1 (en) 2004-07-01 2007-01-31 Human anti-KIR antibody.
US12/244,170 US8119775B2 (en) 2004-07-01 2008-10-02 Human anti-KIR antibodies
US13/347,832 US8614307B2 (en) 2004-07-01 2012-01-11 Nucleic acids encoding human anti-kir antibodies
US13/936,486 US8981065B2 (en) 2004-07-01 2013-07-08 Human anti-KIR antibodies
US14/659,045 US20150191547A1 (en) 2004-07-01 2015-03-16 Human anti-kir antibodies
US14/829,170 US20150344576A1 (en) 2004-07-01 2015-08-18 Human anti-kir antibodies
NO20171133A NO344566B1 (en) 2004-07-01 2017-07-07 Isolated antibody or fragment thereof, nucleic acid encoding said antibody or antibody fragment, vector comprising the nucleic acid, cell comprising the vector or hybridoma expressing the antibody or antibody fragment, method of making antibody or antibody fragment, pharmaceutical composition comprising said antibody fragment or method production of antibody.
CY20191100871T CY1122391T1 (en) 2004-07-01 2019-08-13 PAN-KIR2DL NK-RECEPTOR ANTIBODIES AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IBPCT/IB2004/002464 2004-07-01
PCT/IB2004/002464 WO2005003172A2 (en) 2003-07-02 2004-07-01 Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
DKPCT/DK2004/000470 2004-07-01
PCT/DK2004/000470 WO2005003168A2 (en) 2003-07-02 2004-07-01 Methods for the production and cytotoxicity evaluation of kir2dl nk-receptor antibodies
DKPA200500025 2005-01-06
DKPA200500025 2005-01-06

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11630176 A-371-Of-International 2005-07-01
US12/244,170 Continuation US8119775B2 (en) 2004-07-01 2008-10-02 Human anti-KIR antibodies

Publications (2)

Publication Number Publication Date
WO2006003179A2 WO2006003179A2 (en) 2006-01-12
WO2006003179A3 true WO2006003179A3 (en) 2006-05-26

Family

ID=35431942

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/053122 Ceased WO2006003179A2 (en) 2004-07-01 2005-07-01 Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use

Country Status (10)

Country Link
US (5) US8119775B2 (en)
EP (2) EP1791868B1 (en)
JP (1) JP5112863B2 (en)
CN (1) CN1997670B (en)
AU (1) AU2005259221B2 (en)
CA (1) CA2601417C (en)
DK (1) DK2287195T3 (en)
PL (1) PL2287195T3 (en)
SI (1) SI2287195T1 (en)
WO (1) WO2006003179A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10463049B2 (en) 2015-05-06 2019-11-05 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
US11351252B2 (en) 2016-06-05 2022-06-07 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US12076375B2 (en) 2022-06-29 2024-09-03 Snipr Biome Aps Treating and preventing E coli infections

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0412138B8 (en) 2003-07-02 2021-05-25 Innate Pharma method of selecting a monoclonal antibody, method of selecting a monoclonal antibody or its antigen-binding fragment, method of detecting the presence of nk cells, and method of purifying nk cells from a sample
US20090191213A9 (en) * 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
HUE045639T2 (en) * 2004-07-01 2020-01-28 Novo Nordisk As Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
DK2287195T3 (en) 2004-07-01 2019-08-19 Innate Pharma PAN-KIR2DL NK-RECEPTOR ANTIBODIES AND USE IN DIAGNOSTICS AND THERAPY
DK2112162T3 (en) 2004-07-10 2015-02-23 Fox Chase Cancer Ct Genetically modified human natural killer cell lines
US20090104170A1 (en) * 2004-11-02 2009-04-23 Richard William Wyatt Childs Compositions and methods for treating hyperproliferative disorders
PT1836225E (en) * 2005-01-06 2012-01-10 Novo Nordisk As Kir-binding agents and methods of use thereof
US20090196850A1 (en) * 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
US9447185B2 (en) 2005-10-14 2016-09-20 Innate Pharma, S.A. Compositions and methods for treating proliferative disorders
EP2359834B1 (en) 2006-03-15 2016-11-09 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
AU2013237638B2 (en) * 2007-01-11 2016-10-13 Novo Nordisk A/S Anti-kir antibodies, formulations, and uses thereof
CN101578113B (en) * 2007-01-11 2015-04-22 诺和诺德公司 Anti-KIR antibodies, formulations, and uses thereof
EP2367553B1 (en) 2008-12-05 2017-05-03 Novo Nordisk A/S Combination therapy to enhance nk cell mediated cytotoxicity
WO2011056644A2 (en) 2009-10-28 2011-05-12 Centocor Ortho Biotech Inc. Anti-glp-1r antibodies and their uses
US20130267613A1 (en) * 2010-10-06 2013-10-10 St Jude Children's Research Hospital Molecular-determinant based typing of kir alleles and kir-ligands
AR083957A1 (en) * 2010-11-22 2013-04-10 Innate Pharma Sa TREATMENT TO MODULATE NK CELLS AND METHODS TO TREAT HEMATOLOGICAL MALIGNITY
CA2837184C (en) * 2011-05-25 2021-09-21 Innate Pharma, S.A. Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
EP2723362A1 (en) 2011-06-21 2014-04-30 Innate Pharma NKp46-MEDIATED NK CELL TUNING
CN102617707B (en) * 2011-09-19 2014-01-29 江苏师范大学 Preparation method of actinomycin D new homologue 2-methyl-actinomycin D
HK1198689A1 (en) 2011-10-25 2015-05-29 Prothena Biosciences Limited Antibody formulations and methods
SG10201603411WA (en) 2011-10-28 2016-07-28 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
RS56624B1 (en) 2012-10-02 2018-03-30 Bristol Myers Squibb Co Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
AU2014220668B2 (en) * 2013-02-20 2018-12-13 Innate Pharma A compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
SG10201801205YA (en) 2013-04-09 2018-04-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
AU2013388126B2 (en) 2013-04-29 2019-03-07 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD38 antibodies and fusions to attenuated interferon alpha-2b
MX2016000750A (en) 2013-08-02 2016-08-05 Aduro Biotech Holdings Europe B V COMBINATION OF CD27 AGONISTS AND INHIBITION OF THE IMMUNOLOGICAL CONTROL POINT FOR STIMULATION OF THE IMMUNOLOGICAL SYSTEM.
SMT201900684T1 (en) 2013-08-08 2020-03-13 Cytune Pharma Combined pharmaceutical composition
EP3995507B1 (en) 2013-08-08 2023-10-04 Cytune Pharma Il-15 and il-15ralpha sushi domain based on modulokines
EP3066128B1 (en) * 2013-11-06 2018-10-31 Bristol-Myers Squibb Company Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
RU2016138744A (en) * 2014-04-10 2018-05-11 Оби Фарма Инк. ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATIONS
US11058768B2 (en) * 2014-04-16 2021-07-13 Biocon Ltd. Stable protein formulations comprising a molar excess of sorbitol
UA119352C2 (en) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд COMBINATION OF LENALIDOMIDE OR POMALIDOMIDE AND STRUCTURES OF ANTI-CD38 ANTIBODY-ATHENED INTERPHERONE ALPHA-2B AND METHOD OF TREATMENT38
JP6654781B2 (en) * 2014-08-29 2020-02-26 国立大学法人北海道大学 Monoclonal antibody against KIR2DS1
US11639384B2 (en) 2014-10-28 2023-05-02 University Children's Hospital Tübingen Treatment of pediatric BCP-ALL patients with an anti-KIR antibody
UA125637C2 (en) 2014-10-29 2022-05-11 Тева Фармасьютікалз Острейліа Пті Лтд MERGER INTERFERON POLYPEPTIDE <font face = "Symbol"> a2 </font> b
EP3223865A4 (en) 2014-10-31 2018-10-03 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
CN105669862A (en) * 2014-11-21 2016-06-15 上海中信国健药业股份有限公司 Anti-human PD-L1/KIR bispecific antibody, preparation method and application thereof
JP6895380B2 (en) 2015-02-06 2021-06-30 ナショナル ユニバーシティ オブ シンガポール Methods for Improving the Efficacy of Therapeutic Immune Cells
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
HUE050894T2 (en) 2015-04-17 2021-01-28 Bristol Myers Squibb Co Compositions comprising a combination of ipilimumab and nivolumab
US20180140572A1 (en) 2015-06-03 2018-05-24 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
USD784565S1 (en) * 2015-07-03 2017-04-18 Arktura Llc Architectural fixture
USD777951S1 (en) * 2015-07-03 2017-01-31 Arktura, Llc Architectural fixture
USD771281S1 (en) * 2015-07-03 2016-11-08 Arktura Llc Architectural fixture
USD785212S1 (en) * 2015-07-03 2017-04-25 Arktura Llc Architectural fixture
CN111375066B (en) 2015-07-16 2023-04-25 百欧肯治疗有限公司 Compositions and methods for treating cancer
AU2016299166B2 (en) 2015-07-24 2022-03-31 Innate Pharma Methods for detecting tissue infiltrating NK cells
KR20180104597A (en) 2015-11-07 2018-09-21 멀티비르 인코포레이티드 Compositions comprising tumor suppressor gene therapy and immune blockade for cancer therapy
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
JP7189021B2 (en) 2016-03-16 2022-12-13 アマル セラピューティクス エスエー Combination of an immune checkpoint modulator and a conjugate comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
HUE066655T2 (en) 2016-05-20 2024-08-28 Biohaven Therapeutics Ltd Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers
US10858431B2 (en) * 2016-06-30 2020-12-08 Trellis Bioscience, Llc Monoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling
AU2017331949B2 (en) 2016-09-21 2024-11-14 Amal Therapeutics Sa Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
KR20240142597A (en) 2016-09-27 2024-09-30 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 The method for making the immunity check point blockade therapy reinforced by regulating the microbial genus whole
RU2755903C2 (en) 2016-10-12 2021-09-22 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Methods and compositions for tusc2-immunotherapy
CA3037851A1 (en) 2016-10-21 2018-04-26 Innate Pharma Treatment with anti-kir3dl2 agents
JP2019536480A (en) 2016-11-22 2019-12-19 ナショナル ユニバーシティ オブ シンガポール Blockade of CD7 expression and chimeric antigen receptor for immunotherapy of T cell malignancies
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018099539A1 (en) 2016-11-29 2018-06-07 Horst Lindhofer Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
CA3046961A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
CA3052291A1 (en) * 2017-02-09 2018-08-16 Memorial Sloan Kettering Cancer Center Anti-kir3dl1 antibodies
SG11201908396PA (en) 2017-03-31 2019-10-30 Bristol Myers Squibb Co Methods of treating tumor
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
JP7678493B2 (en) 2017-05-29 2025-05-16 エクセリクシス， インク． Cancer-related immunosuppressant inhibitors
JP2020530291A (en) 2017-08-10 2020-10-22 ナショナル ユニバーシティ オブ シンガポール T cell receptor deficiency chimeric antigen receptor T cells and how to use them
WO2019075468A1 (en) 2017-10-15 2019-04-18 Bristol-Myers Squibb Company Methods of treating tumor
AU2019322487B2 (en) 2018-03-19 2024-04-18 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
TW202003565A (en) 2018-03-23 2020-01-16 美商必治妥美雅史谷比公司 Antibodies against MICA and/or MICB and uses thereof
SG11202009504YA (en) 2018-03-25 2020-10-29 Snipr Biome Aps Treating & preventing microbial infections
US20210032344A1 (en) 2018-03-30 2021-02-04 Bristol-Myers Squibb Company Methods of treating tumor
CA3100386A1 (en) 2018-05-23 2019-11-28 National University Of Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
CN112638375A (en) 2018-06-15 2021-04-09 旗舰创业创新五公司 Increasing immune activity through modulation of post-cellular signaling factors
CN109125247A (en) * 2018-09-06 2019-01-04 广州苿莱生物科技有限公司 The preparation method of adult stem cell freeze-dried powder and its application in cosmetics
MA55805A (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc METHODS OF MODULATING IMMUNE ACTIVITY
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
CN114174538A (en) 2019-05-30 2022-03-11 百时美施贵宝公司 Multiple tumor gene signatures suitable for immunooncology therapy
KR20220016155A (en) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 Methods of Identifying Suitable Subjects for Immuno-Oncology (I-O) Therapy
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
JP2023500506A (en) 2019-11-04 2023-01-06 アストラゼネカ・アクチエボラーグ Combination therapy to treat cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
WO2021245071A1 (en) 2020-06-03 2021-12-09 Mv Biotherapeutics Sa Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof
JP2023532339A (en) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド Viruses engineered to promote sanotransmission and their use in treating cancer
MX2023000197A (en) 2020-07-07 2023-02-22 BioNTech SE THERAPEUTIC RNA FOR HPV POSITIVE CANCER.
JP2023534959A (en) * 2020-07-16 2023-08-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Antibodies against MUC1-C/extracellular domain (MUC1-C/ECD)
CN116438199A (en) 2020-08-31 2023-07-14 百时美施贵宝公司 Cell localization features and immunotherapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
JP2024501029A (en) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Subcutaneous administration of PD1/PD-L1 antibodies
PL4267105T3 (en) 2020-12-28 2025-06-30 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2022169825A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
KR20230165276A (en) 2021-03-31 2023-12-05 플래그쉽 파이어니어링 이노베이션스 브이, 인크. Thanotransmission polypeptides and their use in the treatment of cancer
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
JP2024525475A (en) 2021-06-29 2024-07-12 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド Engineered immune cells to promote tanotransmission and uses thereof
EP4370552A1 (en) 2021-07-13 2024-05-22 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023110937A1 (en) 2021-12-14 2023-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
JP2025509749A (en) 2022-03-18 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー Methods for isolating polypeptides
IL317319A (en) 2022-06-02 2025-01-01 Bristol Myers Squibb Co Antibody compositions and methods of use thereof
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
AU2023369055A1 (en) 2022-10-24 2025-05-15 Cancer Research Technology Limited Tumour sensitisation to checkpoint inhibitors with redox status modifier
WO2024089417A1 (en) 2022-10-24 2024-05-02 Memorial Sloan-Kettering Cancer Center Tumour stratification for responsiveness to an immune checkpoint inhibitor
EP4610277A1 (en) * 2022-10-25 2025-09-03 Daiichi Sankyo Company, Limited Method for avoiding immune rejection using agonist for inhibitory kir
IL321098A (en) 2022-12-14 2025-07-01 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
EP4649173A1 (en) 2023-01-13 2025-11-19 Akrivia Biomedics Limited Method of profiling diseases
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026671A1 (en) * 1998-10-29 2000-05-11 Connex Gmbh Detection of acid-resistant micro-organisms in a stool

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550019A (en) 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (en) 1990-08-29 1997-09-15 Genpharm Int PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69133557D1 (en) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv HOMOLOGOUS RECOMBINATION IN MAMMALIAN CELLS
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
JPH0515592A (en) 1991-07-05 1993-01-26 Morishita Roussel Kk Method, device and appliance for administering flowable nutriments dropwise
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JPH05112863A (en) 1991-10-21 1993-05-07 Nippon Steel Corp Formation of thin film
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994000569A1 (en) 1992-06-18 1994-01-06 Genpharm International, Inc. Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
AU675661B2 (en) 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies
ES2146648T3 (en) 1993-03-09 2000-08-16 Genzyme Corp PROCEDURE FOR ISOLATION OF MILK PROTEINS.
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5539094A (en) 1993-11-12 1996-07-23 La Jolla Cancer Research Foundation DNA encoding Bcl-2-associated proteins
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5583034A (en) 1994-02-22 1996-12-10 La Jolla Institute For Allergy And Immunology Enhancement of adoptosis using antisense oligonucleotides
US5808028A (en) 1994-05-24 1998-09-15 The United States Of America As Represented By The Department Of Health And Human Services Molecular clone of a P58 receptor protein and uses thereof
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
NZ298145A (en) 1994-12-29 1998-08-26 Yamanouchi Pharma Co Ltd Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
WO1996033266A1 (en) 1995-04-21 1996-10-24 Cell Genesys, Inc. Generation of large genomic dna deletions
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
AU2978899A (en) 1998-03-03 1999-09-20 Abgenix, Inc. Cd147 binding molecules as therapeutics
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EE05483B1 (en) 1998-12-23 2011-10-17 Pfizer, Inc. Human monoclonal antibodies to CTLA-4
US6887468B1 (en) 1999-04-28 2005-05-03 Board Of Regents, The University Of Texas System Antibody kits for selectively inhibiting VEGF
KR100419555B1 (en) 2000-05-29 2004-02-19 주식회사유한양행 A variable region of the monoclonal antibody against a s-surface antigen of hepatitis b virus and a gene encoding the same
US20030095965A1 (en) 2001-05-02 2003-05-22 Katrien Van Beneden Antibodies to Ly49E and CD94/NKG2 receptors
CN1533438A (en) 2001-06-08 2004-09-29 �����Ŵ��Ƽ���˾ Method for producing protein in plant
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
CN1652821A (en) 2002-01-28 2005-08-10 米德列斯公司 Human monoclonal antibody against prostate-specific membrane antigen (PSMA)
BRPI0412138B8 (en) 2003-07-02 2021-05-25 Innate Pharma method of selecting a monoclonal antibody, method of selecting a monoclonal antibody or its antigen-binding fragment, method of detecting the presence of nk cells, and method of purifying nk cells from a sample
US7803376B2 (en) * 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
KR20050111185A (en) * 2004-05-21 2005-11-24 삼성에스디아이 주식회사 Plasma display panel
DK2287195T3 (en) 2004-07-01 2019-08-19 Innate Pharma PAN-KIR2DL NK-RECEPTOR ANTIBODIES AND USE IN DIAGNOSTICS AND THERAPY
DK1835937T3 (en) * 2005-01-06 2012-07-23 Novo Nordisk As Compositions and Methods for Treating Viral Infection
PT1836225E (en) * 2005-01-06 2012-01-10 Novo Nordisk As Kir-binding agents and methods of use thereof
EP2367553B1 (en) * 2008-12-05 2017-05-03 Novo Nordisk A/S Combination therapy to enhance nk cell mediated cytotoxicity
CA2837184C (en) * 2011-05-25 2021-09-21 Innate Pharma, S.A. Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026671A1 (en) * 1998-10-29 2000-05-11 Connex Gmbh Detection of acid-resistant micro-organisms in a stool

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BARTEN R ET AL: "Divergent and convergent evolution of NK-cell receptors", TRENDS IN IMMUNOLOGY, ELSEVIER, CAMBRIDGE, GB, vol. 22, no. 1, 1 January 2001 (2001-01-01), pages 52 - 57, XP004255853, ISSN: 1471-4906 *
DATABASE Geneseq [online] 22 April 2003 (2003-04-22), "Mouse antibody 3E11 light chain variable region.", XP002309299, retrieved from EBI accession no. GSN:ABG74248 Database accession no. ABG74248 *
FARAG SHERIF S ET AL: "Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect", BLOOD, vol. 100, no. 6, 15 September 2002 (2002-09-15), pages 1935 - 1947, XP002308880, ISSN: 0006-4971 *
KOH CRYSTAL Y ET AL: "NK inhibitory-receptor blockade for purging of leukemia: effects on hematopoietic reconstitution.", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION : JOURNAL OF THE AMERICAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION. 2002, vol. 8, no. 1, 2002, pages 17 - 25, XP002308879, ISSN: 1083-8791 *
MORETTA ALESSANDRO ET AL: "Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis", ANNUAL REVIEW OF IMMUNOLOGY ANNUAL REVIEWS {A}, 4139 EL CAMINO WAY, PALO ALTO, CA, 94303-0139, USA SERIES : ANNUAL REVIEW OF IMMUNOLOGY (ISSN 0732-0582), 2001, pages 197 - 223, XP008016880, ISSN: 0-8243-3019-6 *
MORETTA ALESSANDRO ET AL: "Receptors for HLA class-I molecules in human natural killer cells", ANNUAL REVIEW OF IMMUNOLOGY ANNUAL REVIEWS INC. {A}, P.O. BOX 10139, 4139 EL CAMINO WAY, PALO ALTO, CALIFORNIA 94306, USA SERIES : ANNUAL REVIEW OF IMMUNOLOGY (ISSN 0732-0582), 1996, pages 619 - 648, XP002308882, ISSN: 0-8243-3014-5 *
POGGI A ET AL: "P40, A NOVEL SURFACE MOLECULE INVOLVED IN THE REGULATION OF THE NON-MAJOR HISTOCOMPATIBILITY COMPLEX-RESTRICTED CYTOLYTIC ACTIVITY IN HUMANS", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 25, no. 2, 1995, pages 369 - 376, XP009041151, ISSN: 0014-2980 *
SHIN JEON-SOO ET AL: "Monoclonal antibodies with various reactivity to p58 killer inhibitory receptors", HYBRIDOMA, vol. 18, no. 6, December 1999 (1999-12-01), pages 521 - 527, XP001041418, ISSN: 0272-457X *
SPAGGIARI GRAZIA MARIA ET AL: "Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction.", BLOOD, vol. 100, no. 12, 1 December 2002 (2002-12-01), pages 4098 - 4107, XP002308878, ISSN: 0006-4971 *
WARREN H S ET AL: "Functional analysis of CD158b monoclonal antibodies recognizing the killer Ig-like receptors KIR2DS2, KIR2DL2 and KIR2DL3", TISSUE ANTIGENS, vol. 55, no. Supplement 1, 2000, & 7TH WORKSHOP AND CONFERENCE ON HUMAN LEUCOCYTE DIFFERENTIATION ANTIGENS; HARROGATE, ENGLAND, UK; JUNE 20-24, 2000, pages 80 - 81, XP009040899, ISSN: 0001-2815 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12226430B2 (en) 2015-05-06 2025-02-18 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US10463049B2 (en) 2015-05-06 2019-11-05 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US10524477B2 (en) 2015-05-06 2020-01-07 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US10561148B2 (en) 2015-05-06 2020-02-18 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US10582712B2 (en) 2015-05-06 2020-03-10 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US10624349B2 (en) 2015-05-06 2020-04-21 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11147830B2 (en) 2015-05-06 2021-10-19 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11517582B2 (en) 2015-05-06 2022-12-06 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US10506812B2 (en) 2015-05-06 2019-12-17 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11642363B2 (en) 2015-05-06 2023-05-09 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11400110B2 (en) 2015-05-06 2022-08-02 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11612617B2 (en) 2015-05-06 2023-03-28 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11844760B2 (en) 2015-05-06 2023-12-19 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11547716B2 (en) 2015-05-06 2023-01-10 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11471530B2 (en) 2016-06-05 2022-10-18 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US11351252B2 (en) 2016-06-05 2022-06-07 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US12318445B2 (en) 2016-06-05 2025-06-03 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US11485973B2 (en) 2018-04-30 2022-11-01 Snipr Biome Aps Treating and preventing microbial infections
US11421227B2 (en) 2018-04-30 2022-08-23 Snipr Biome Aps Treating and preventing microbial infections
US11643653B2 (en) 2018-04-30 2023-05-09 Snipr Biome Aps Treating and preventing microbial infections
US11788085B2 (en) 2018-04-30 2023-10-17 Snipr Biome Aps Treating and preventing microbial infections
US10920222B2 (en) 2018-04-30 2021-02-16 Snipr Biome Aps Treating and preventing microbial infections
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
US12448619B2 (en) 2018-04-30 2025-10-21 Snipr Biome Aps Treating and preventing microbial infections
US12076375B2 (en) 2022-06-29 2024-09-03 Snipr Biome Aps Treating and preventing E coli infections

Also Published As

Publication number Publication date
CN1997670A (en) 2007-07-11
US8981065B2 (en) 2015-03-17
SI2287195T1 (en) 2019-08-30
JP2008506368A (en) 2008-03-06
JP5112863B2 (en) 2013-01-09
EP1791868A2 (en) 2007-06-06
US20090081240A1 (en) 2009-03-26
AU2005259221A1 (en) 2006-01-12
EP2287195B1 (en) 2019-05-15
EP2287195A2 (en) 2011-02-23
CN1997670B (en) 2014-04-30
WO2006003179A2 (en) 2006-01-12
EP2287195A3 (en) 2013-12-04
CA2601417C (en) 2018-10-30
EP1791868B1 (en) 2011-02-23
PL2287195T3 (en) 2019-10-31
US8614307B2 (en) 2013-12-24
CA2601417A1 (en) 2006-01-12
US20150344576A1 (en) 2015-12-03
US20150191547A1 (en) 2015-07-09
US20130287770A1 (en) 2013-10-31
AU2005259221B2 (en) 2011-02-10
US8119775B2 (en) 2012-02-21
DK2287195T3 (en) 2019-08-19
US20120208237A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
WO2006003179A3 (en) Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
WO2005003172A3 (en) Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
PH12021552002A1 (en) Anti-trem2 antibodies and methods of use thereof
WO2003038043A3 (en) Combinations of dr5 antibody and other therapeutic agents
AU2013205271B2 (en) Human CGRP receptor binding proteins
WO2007009064A3 (en) Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
EP2143795A3 (en) Anti-CD20 monoclonal antibody
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
WO2004083249A3 (en) Antibodies against human il-21 receptor and uses therefor
WO2004078938A3 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
WO2006002177A3 (en) Interferon alpha receptor 1 antibodies and their uses
WO2005058815A3 (en) Ip-10 antibodies and their uses
PL377337A1 (en) Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
WO2005012479A3 (en) Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
MX2009010092A (en) Apoptotic anti- ige antibodies binding the membrane-bound ige.
TNSN07036A1 (en) Human monoclonal antibodies against human il-4
WO2006029220A3 (en) Combination therapy with anti-ctla4 and anti-4-1bb antibodies
MX2007000210A (en) Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use.
WO2024030956A3 (en) Cd39-specific binding agents and methods of using the same
WO2019241721A3 (en) Compositions and methods relative to igm memory b cells
WO2011050104A3 (en) Methods of using anti-cd3 antibodies to prevent weight gain
TH92681A (en) Pharmaceutical Ingredients, Antibody Antibodies, CD40 Antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 179635

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 7162/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005259221

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007518617

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005758642

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005259221

Country of ref document: AU

Date of ref document: 20050701

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2601417

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2005259221

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077000069

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 200580022633.1

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2007/000210

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007/00736

Country of ref document: ZA

Ref document number: 200700736

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2006144820

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 1020077000069

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005758642

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0512911

Country of ref document: BR